Bill Ketelbey

Dr Bill Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional with 30 years experience in the industry, including senior medical and management roles with global pharmaceutical giant, Pfizer. Prior to joining Actinogen Medical, Dr Ketelbey was regional vice president of Medical Affairs for Pfizer’s Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea, and country medical director for Pfizer Australia and New Zealand. Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s disease. At Pfizer, Dr Ketelbey led the Australian/New Zealand clinical development, and was involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer’s disease therapy locally and globally. He was also involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer’s. Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa, a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom, an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.